All In Biotech

Drug Trial Radar · NCT02373280

The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection

A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori

Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Aug 2014

Primary completion

Apr 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Seoul National University Bundang HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 27, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.

Conditions

  • Helicobacter Infection

Interventions

  • 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)Drug

    In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).

  • 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)Drug

    the participants received PPI based triple therapy\[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\]

  • 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]Drug

    moxifloxacin triple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)\].

  • 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)Drug

    bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compare the percentage of participants with successful H. pylori eradication in each groupsTime frame: 6 weeks after completion of eradication

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.